 |
|
Livedoid Vasculopathy
Further Evidence for Procoagulant Pathogenesis
Bethany R. Hairston, MD;
Mark D. P. Davis, MD;
Mark R. Pittelkow, MD;
Iftikhar Ahmed, MD
Arch Dermatol. 2006;142:1413-1418.
Objective To further characterize the clinical and pathologic features, disease associations, and laboratory abnormalities of livedoid vasculopathy.
Design Retrospective study of patients identified from our institutional database from January 1, 1990, to December 31, 2000.
Setting Tertiary care institution.
Patients Forty-five patients with biopsy-proved livedoid vasculopathy.
Main Outcome Measures Clinical presentation, histopathologic diagnosis, results of testing for coagulation abnormalities, and assessment of vascular status.
Results Thirty-two patients (71.1%) were female (mean age, 45 years; age range, 10-85 years). Bilateral lower extremity disease occurred in 36 patients (80.0%), ulceration in 31 (68.9%), and atrophie blanche in 32 (71.1%). In patients tested, transcutaneous oximetry measurements were decreased in 20 (74.1%) of 27, and factor V Leiden mutation (heterozygous) was noted in 2 (22.2%) of 9, decreased activity for protein C or protein S in 2 (13.3%) of 15, prothrombin G20210A gene mutation in 1 (8.3%) of 12, and lupus anticoagulant in 5 (17.9%) of 28. Anticardiolipin antibodies were present in 8 (28.6%) of 28 patients, and elevated homocysteine levels in 3 (14.3%) of 21. Intraluminal thrombosis was observed in 44 (97.8%) of 45 skin biopsy specimens. Direct immunofluorescence disclosed multiple vascular conjugates in 31 (86.1%) of 36 biopsy specimens.
Conclusions Livedoid vasculopathy was predominantly bilateral, affected the lower extremities, and was associated with ulceration and atrophie blanche. Histologic evidence of intraluminal thrombosis was observed in almost all biopsy specimens reviewed. Laboratory testing revealed numerous heterogeneous coagulation abnormalities, providing further evidence of procoagulant mechanisms.
Author Affiliations: Departments of Dermatology (Drs Hairston, Davis, Pittelkow, and Ahmed) and Laboratory Medicine and Pathology (Dr Ahmed), Mayo Clinic, Rochester, Minn.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Livedoid Vasculopathy Associated With Plasminogen Activator Inhibitor-1 Promoter Homozygosity (4G/4G) Treated Successfully With Tissue Plasminogen Activator
April Deng, Christopher D. Gocke, John Hess, Meyer Heyman, Michael Paltiel, and Anthony Gaspari
Arch Dermatol. 2006;142(11):1466-1469.
ABSTRACT
| FULL TEXT
Livedoid Vasculopathy: What It Is and How the Patient Should Be Evaluated and Treated
Jeffrey P. Callen
Arch Dermatol. 2006;142(11):1481-1482.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Case 5-2009 -- A 47-Year-Old Woman with a Rash and Numbness and Pain in the Legs
Kroshinsky et al.
NEJM 2009;360:711-720.
FULL TEXT
Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinaemia
Casato et al.
Rheumatology (Oxford) 2008;47:1659-1663.
ABSTRACT
| FULL TEXT
Hyperhomocysteinemia and Lower Extremity Wounds
Schwartzfarb and Romanelli
INT J LOW EXTREM WOUNDS 2008;7:126-136.
ABSTRACT
Lymphocytic Thrombophilic Arteritis: A Newly Described Medium-Sized Vessel Arteritis of the Skin
Lee et al.
Arch Dermatol 2008;144:1175-1182.
ABSTRACT
| FULL TEXT
Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy
Zeni et al.
Ann Rheum Dis 2008;67:1055-1056.
FULL TEXT
Livedoid vasculopathy: what it is and how the patient should be evaluated and treated.
Callen
Arch Dermatol 2006;142:1481-1482.
FULL TEXT
|
